The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Early findings of anti-IL-1β therapy for preventing precancer progression in lung cancer
Jianjun Zhang, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses interim results from a clinical trial investigating the use of anti-interleukin-1β antibody, canakinumab, for the prevention of precancerous lesions progressing into invasive lung cancer. Studies from Dr. Zhang’s lab and others have shown the significant role of the IL-1β pathway and macrophages in precancer development and progression. Animal models demonstrated that targeting this pathway could enhance anti-tumor immunity and reduce invasive lung cancer. The interim analysis presented at the World Conference on Lung Cancer (WCLC) 2024 included 15 patients, with 11 showing nodule shrinkage and the drug being well tolerated. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
